Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, and ISTODAX®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These candidates include our IMiDs® compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to our leading oral anti-inflammatory agents and cellular therapies. We believe our commercial stage products and the depth of our product pipeline, provide the catalysts for future growth.
May 19, 2015
Analysis of Phase II Data for Celgene's Investigational Oral GED-0301 in Patients with Active Crohn's Disease Presented at Digestive Disease Week
May 13, 2015
Celgene Announces Presentations of Investigational Studies in Solid Tumor and Blood Cancers at ASCO 2015
May 28, 2015 at 3:00 PM ET
May 31, 2015 at 7:30 PM ET